Subcutaneous epoetin-alpha every one, two, and three weeks in renal anemia

Journal of Nephrology

Volumn 15, Issue 5, 2002, Pages 565-574

  Piccoli, Antonio ^a   Malagoli, Andrea ^a   Komninos, Georgios ^a   Pastori, Giordano ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Anemia; Dialysis; Epoetin; Erythropoietin; K DOQI; Renal failure

Indexed keywords

ACETYLSALICYLIC ACID; ALKALINE PHOSPHATASE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; FERROUS SULFATE; HEMOGLOBIN; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD PRESSURE; CAUCASIAN; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TARGETING; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INJECTION; KIDNEY ANEMIA; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; POTENTIOMETRIC TITRATION; RETROSPECTIVE STUDY; SIDE EFFECT; TIME SERIES ANALYSIS;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANEMIA, HYPOCHROMIC; COHORT STUDIES; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPOETIN ALFA; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROBABILITY; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0036760032     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Besarab A, Samarapungavan D. Treatment of anemia in dialysis patients. In: Henrich WL, Ed. Principles and Practice of Dialysis (2nd edn). Baltimore: Williams & Wilkins 1999; 398-436.
2. Besarab A. Optimizing epoetin therapy in end-stage renal disease: The case for subcutaneous administration. Am J Kidney Dis 1993; 22 (suppl 1): S13-22.
3. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 1997; 30 (suppl 1): S192-240.
4. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: Update 2000. Am J Kidney Dis 2001; 37 (suppl 1): S182-238.
5. Kaufman J, Reda DJ, Fye CL. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med 1998; 339: 578-83.
6. Thomas M, Saker BM, Thatcher GN, Hurst PE, Moody H. Cost-effectiveness of weekly and fortnightly subcutaneous erythropoietin. Lancet 1990; 335: 1533-4.
7. Stevens ME, Summerfield GP, Hall AA, Beck CA, Harding AJ, Cove-Smith JR, Paterson AD. Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end-stage renal disease. Br Med J 1992; 304: 474-7.
8. Austrian Multicenter Study Group of r-HuEPO in predialysis patients: Effectiveness and safety of recombinant human erythropoitin in predialysis patients. Nephron 1992; 61: 399-403.
9. Nomoto Y, Kawaguchi Y, Kubota M, Tagawa H, Kubo K, Ogura Y, Shoji T, Kawada Y, Koshikawa S, Mimura N. A multicenter study with once a week or once every two weeks high-dose subcutaneous administration of recombinant human erythropoietin in continuous ambulatory peritoneal dialysis. Perit Dial Int 1994; 14: 56-60.
10. Piccoli A, Puggia RM, Fusaro M, Favaro E, Pillon L. A decision analysis comparing three dosage regimens of subcutaneous epoetin in continuous ambulatory peritoneal dialysis. Pharmacoeconomics 1995; 7: 444-456.
11. Weiss LG, Clyne N, Divino Fihlho J, Frisenette-Fich C, Kurkus J, Svensson B, Swedish Study Group. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin β: Results from a randomised controlled multicentre trial. Nephrol Dial Transplant 2000; 15: 2014-9.
12. Eschbach JW, Abdulhadi MH, Browne JK, Degano BG, Downing MR, Egri JC, Evans RW, Friedman ED, Graber SE, Haley NR. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a Phase III multicenter clinical trial. Ann Intern Med 1989; 111: 992-1000.
13. Kulzer P, Schaeffer RM, Krahn R, Schaeffer L, Heidland A, European Multicenter Study Group. Effectiveness and safety of recombinant human erythropoietin (r-HuEPO) in the treatment of anemia of chronic renal failure in non dialysis patients. Int J Artif Organs 1994; 17: 195-202.
14. Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, Egrie J. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999; 10: 2392-5.
15. Macdougall IC. Novel erythropoiesis stimulating protein. Semin Nephrol 2000; 20: 375-381.
16. Locatelli F, Olivares J, Walker R, Wilkie M, Jenkins B, Dewey C, Gray S, European/ Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001; 60: 741-7.
17. Dixon WJ, Brown MB, Engelman L, Jennrich RI. BMDP Statistical Software Manual. Berkeley: UCLA, 1992.
18. Lentner C. Introduction to statistics. Statistical tables. Mathematical formulae. In Geigy Scientific Tables (vol 2, 8th edn). Basle: Ciba-Geigy Limited 1982; 89-102.
19. TreeAge software Inc. Data 3.5 for Healthcare User's Manual. Williamstown, 1999.